The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5114-5121

  Mendez, Susana ^a   Traslavina, Ryan ^a   Hinchman, Meleana ^a   Huang, Lu ^a   Green, Patricia ^a   Cynamon, Michael H ^b   Welch, John T ^c  

^a Department of Obstetrics Gynecology   (United States)

^b SYRACUSE VA MEDICAL CENTER   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 12; NITRIC OXIDE; PYRAZINAMIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VIVO STUDY; LEISHMANIA MAJOR; MACROPHAGE ACTIVATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN EXPRESSION; SKIN LEISHMANIASIS; SURVIVAL;

ANIMALS; ANTIGENS, CD80; ANTIGENS, CD86; ANTIPROTOZOAL AGENTS; ANTITUBERCULAR AGENTS; CELL LINE; CELL SURVIVAL; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; INTERLEUKIN-10; INTERLEUKIN-12; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MICE; MICE, INBRED BALB C; NITRIC OXIDE; PYRAZINAMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 71249131221     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01146-09     Document Type: Article

References (33)

1. Alvar, J., P. Aparicio, A. Aseffa, M. Den Boer, C. Canavate, J. P. Dedet, L. Gradoni, R. Ter Horst, R. Lopez-Velez, and J. Moreno. 2008. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev. 21:334-359, table of contents.
2. Antinori, S., E. Gianelli, S. Calattini, E. Longhi, M. Gramiccia, and M. Corbellino. 2005. Cutaneous leishmaniasis: an increasing threat for travellers. Clin. Microbiol. Infect. 11:343-346.
3. Aronson, S. 2007. The Bagdad boil deploys to the United States. Med. Health R. I. 90:231.
4. Belkaid, Y., S. Kamhawi, G. Modi, J. Valenzuela, N. Noben-Trauth, E. Rowton, J. Ribeiro, and D. L. Sacks. 1998. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J. Exp. Med. 188:1941-1953.
5. Chappuis, F., S. Sundar, A. Hailu, H. Ghalib, S. Rijal, R. W. Peeling, J. Alvar, and M. Boelaert. 2007. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5:873-882.
6. Chong, C. R., and D. J. Sullivan, Jr. 2007. New uses for old drugs. Nature 448:645-646.
7. Coleman, R. E., D. A. Burkett, V. Sherwood, J. Caci, S. Spradling, B. T. Jennings, E. Rowton, W. Gilmore, K. Blount, C. E. White, and J. L. Putnam. 2007. Impact of phlebotomine sand flies on U.S. military operations at Tallil Air Base, Iraq. 2. Temporal and geographic distribution of sand flies. J. Med. Entomol. 44:29-41.
8. Cuna, W. R., R. Velasquez, J. Riva, I. Guachalla, and C. Rodriguez. 2007. Enhancement of a t(h)1 immune response in amphotericin B-treated mucocutaneous leishmaniasis. J. Biomed. Biotechnol. 2007:96410.
9. Cynamon, M. H., S. P. Klemens, T. S. Chou, R. H. Gimi, and J. T. Welch. 1992. Antimycobacterial activity of a series of pyrazinoic acid esters. J. Med. Chem. 35:1212-1215.
10. Desjeux, P. 2004. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27:305-318.
11. Doggrell, S. A. 2005. New drugs being developed for the treatment of tuberculosis. Expert Opin. Investig. Drugs 14:917-920.
12. Halsey, E. S., L. M. Bryce, G. W. Wortmann, P. J. Weina, J. R. Ryan, and C. C. DeWitt. 2004. Visceral leishmaniasis in a soldier returning from Operation Enduring Freedom. Mil. Med. 169:699-701.
13. Harding, C. V. 2001. Choosing and preparing antigen-presenting cells. Curr. Protoc. Immunol., chapter 16, unit 16.1.
14. Kern, F., and J. K. Pedersen. 1973. Leishmaniasis in the United States. A report of ten cases in military personnel. JAMA 226:872-874.
15. Klemens, S. P., C. A. Sharpe, and M. H. Cynamon. 1996. Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility. Antimicrob. Agents Chemother. 40: 14-16.
16. Lee, S. H., J. L. Stephens, K. S. Paul, and P. T. Englund. 2006. Fatty acid synthesis by elongases in trypanosomes. Cell 126:691-699. (Pubitemid 44233626)
17. Livore, V. I., K. E. Tripodi, and A. D. Uttaro. 2007. Elongation of polyunsaturated fatty acids in trypanosomatids. FEBS J. 274:264-274. (Pubitemid 44952914)
18. Magill, A. J., M. Grogl, R. A. Gasser, Jr., W. Sun, and C. N. Oster. 1993. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N. Engl. J. Med. 328:1383-1387.
19. Mendez, S., M. Nell, F. J. Fernandez-Perez, and J. M. Alunda. 1999. Sensi- tivity of Leishmania infantum amastigotes to fluorinated L-ornithine analogues. Med. Sci. Res. 1999:87-89.
20. Morris-Jones, S. D., and A. D. Bryceson. 1990. Cutaneous leishmaniasis after expedition to Panama. Lancet 336:691-692.
21. Ngo, S. C., O. Zimhony, W. J. Chung, H. Sayahi, W. R. Jacobs, Jr., and J. T. Welch. 2007. Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrob. Agents Chemother. 51: 2430-2435.
22. Reithinger, R., and P. G. Coleman. 2007. Treating cutaneous leishmaniasis patients in Kabul, Afghanistan: cost-effectiveness of an operational program in a complex emergency setting. BMC Infect. Dis. 7:3.
23. Roberts, C. W., R. McLeod, D. W. Rice, M. Ginger, M. L. Chance, and L. J. Goad. 2003. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol. 126:129-142.
24. Sanchez, J. L., B. M. Diniega, J. W. Small, R. N. Miller, J. M. Andujar, P. J. Weina, P. G. Lawyer, W. R. Ballou, and J. K. Lovelace. 1992. Epidemiologic investigation of an outbreak of cutaneous leishmaniasis in a defined geographic focus of transmission. Am. J. Trop. Med. Hyg. 47:47-54.
25. Sayahi, H., S. Putamadappa, S. C. Ngo, W. R. Jacobs, A. Shekhtman, J. T. Welch, and O. Zimhony. 2007. Saturation transfer difference NMR studies on the binding of the antitubercular agent pyrazinamide to Mycobacterium tuberculosis fatty acid synthase I, abstr. C1-1495. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
26. Spath, G. F., and S. M. Beverley. 2001. A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation. Exp. Parasitol. 99:97-103.
27. Speirs, R. J., J. T. Welch, and M. H. Cynamon. 1995. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide. Antimicrob. Agents Chemother. 39:1269-1271.
28. Sundar, S., and M. Chatterjee. 2006. Visceral leishmaniasis - current therapeutic modalities. Indian J. Med. Res. 123:345-352.
29. Woodrow, J. P., J. D. Hartzell, J. Czarnik, D. M. Brett-Major, and G. Wortmann. 2006. Cutaneous and presumed visceral leishmaniasis in a soldier deployed to Afghanistan. MedGenMed 8:43.
30. Yeager, R. L., W. G. Munroe, and F. I. Dessau. 1952. Pyrazinamide (aldinamide*) in the treatment of pulmonary tuberculosis. Trans. Annu. Meet. Natl. Tuberc. Assoc. 48:178-201.
31. Zanoni, I., R. Ostuni, G. Capuano, M. Collini, M. Caccia, A. E. Ronchi, M. Rocchetti, F. Mingozzi, M. Foti, G. Chirico, B. Costa, A. Zaza, P. Ricciardi- Castagnoli, and F. Granucci. 2009. CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature 460:264-268.
32. Zhu, M., J. R. Starke, W. J. Burman, P. Steiner, J. J. Stambaugh, D. Ashkin, A. E. Bulpitt, S. E. Berning, and C. A. Peloquin. 2002. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 22:686-695. (Pubitemid 34596476)
33. Zimhony, O., J. S. Cox, J. T. Welch, C. Vilcheze, and W. R. Jacobs, Jr. 2000. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. 6:1043-1047.